Citadel Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.3M Buy
+191,051
New +$13.5M ﹤0.01% 2954
2025
Q4
Sell
-244,801
Closed -$16.5M 13209
2025
Q3
$18M Sell
244,801
-66,597
-21% -$4.42M ﹤0.01% 2474
2025
Q2
$16.2M Buy
311,398
+231,991
+292% +$13.2M ﹤0.01% 2400
2025
Q1
$5.07M Sell
79,407
-1,183,350
-94% -$68.7M ﹤0.01% 3848
2024
Q4
$60.4M Buy
+1,262,757
New +$64.8M 0.01% 1117
2024
Q3
Sell
-347,699
Closed -$19.9M 14611
2024
Q2
$18.2M Buy
347,699
+46,333
+15% +$2.03M ﹤0.01% 2087
2024
Q1
$12.3M Buy
301,366
+116,602
+63% +$4.37M ﹤0.01% 2658
2023
Q4
$6.83M Buy
184,764
+254
+0.1% +$9.57K ﹤0.01% 3359
2023
Q3
$7.05M Sell
184,510
-967,309
-84% -$39.6M ﹤0.01% 3148
2023
Q2
$41.5M Buy
1,151,819
+230,398
+25% +$7.86M 0.01% 1206
2023
Q1
$35.2M Buy
921,421
+669,147
+265% +$31.4M 0.01% 1391
2022
Q4
$14.4M Buy
252,274
+232,326
+1,165% +$11.9M ﹤0.01% 2351
2022
Q3
$789K Sell
19,948
-522,398
-96% -$23.1M ﹤0.01% 7499
2022
Q2
$23.9M Buy
542,346
+532,478
+5,396% +$23M 0.01% 1664
2022
Q1
$394K Sell
9,868
-137,702
-93% -$4.9M ﹤0.01% 9943
2021
Q4
$5.93M Buy
147,570
+80,421
+120% +$3M ﹤0.01% 4003
2021
Q3
$2.73M Sell
67,149
-37,252
-36% -$1.56M ﹤0.01% 5582
2021
Q2
$4.74M Sell
104,401
-62,785
-38% -$2.78M ﹤0.01% 4564
2021
Q1
$6.97M Buy
167,186
+4,559
+3% +$208K ﹤0.01% 3593
2020
Q4
$6.95M Sell
162,627
-42,773
-21% -$1.54M ﹤0.01% 3133
2020
Q3
$5.4M Sell
205,400
-84,316
-29% -$2.35M ﹤0.01% 3034
2020
Q2
$7.77M Sell
289,716
-90,572
-24% -$2.04M ﹤0.01% 2523
2020
Q1
$6.84M Buy
380,288
+98,911
+35% +$1.88M ﹤0.01% 2313
2019
Q4
$4.99M Buy
281,377
+8,439
+3% +$146K ﹤0.01% 3082
2019
Q3
$4.23M Sell
272,938
-655,754
-71% -$10.8M ﹤0.01% 3334
2019
Q2
$16M Buy
928,692
+310,599
+50% +$5.01M 0.01% 1647
2019
Q1
$9.95M Buy
618,093
+368,770
+148% +$5.98M ﹤0.01% 2082
2018
Q4
$3.65M Sell
249,323
-3,299
-1% -$52.6K ﹤0.01% 3250
2018
Q3
$4.59M Buy
252,622
+127,877
+103% +$2.24M ﹤0.01% 3123
2018
Q2
$2.1M Buy
124,745
+70,296
+129% +$1.33M ﹤0.01% 4033
2018
Q1
$1.07M Sell
54,449
-96,814
-64% -$1.87M ﹤0.01% 4715
2017
Q4
$3.06M Buy
151,263
+125,642
+490% +$2.31M ﹤0.01% 3067
2017
Q3
$445K Sell
25,621
-211,157
-89% -$2.86M ﹤0.01% 5490
2017
Q2
$3.04M Buy
236,778
+206,052
+671% +$2.75M ﹤0.01% 2645
2017
Q1
$398K Sell
30,726
-222,226
-88% -$2.81M ﹤0.01% 5416
2016
Q4
$2.5M Buy
252,952
+221,260
+698% +$2.42M ﹤0.01% 2693
2016
Q3
$383K Sell
31,692
-13,913
-31% -$142K ﹤0.01% 5268
2016
Q2
$394K Buy
+45,605
New +$450K ﹤0.01% 4810
2016
Q1
Sell
-89,623
Closed -$843K 7243
2015
Q4
$1.55M Sell
89,623
-189,870
-68% -$3.03M ﹤0.01% 3031
2015
Q3
$3.75M Buy
279,493
+245,332
+718% +$4.93M ﹤0.01% 2231
2015
Q2
$771K Sell
34,161
-242,774
-88% -$4.27M ﹤0.01% 4332
2015
Q1
$3.96M Buy
276,935
+255,605
+1,198% +$3.69M ﹤0.01% 2275
2014
Q4
$206K Sell
21,330
-170,708
-89% -$1.52M ﹤0.01% 5951
2014
Q3
$1.75M Sell
192,038
-5,160
-3% -$49.1K ﹤0.01% 3004
2014
Q2
$1.95M Buy
197,198
+107,293
+119% +$910K ﹤0.01% 2751
2014
Q1
$1.14M Sell
89,905
-41,659
-32% -$618K ﹤0.01% 3269
2013
Q4
$1.97M Buy
131,564
+97,497
+286% +$1.25M ﹤0.01% 2565
2013
Q3
$376K Sell
34,067
-427,587
-93% -$3.56M ﹤0.01% 4112
2013
Q2
$3.67M Buy
+461,654
New +$2.94M 0.01% 1860

Other funds holding HALO

Citadel Advisors's HALO Position: Q1 2026 in Review

Citadel Advisors opened a new position in Halozyme (HALO) in Q1 2026: 191,051 shares worth $12.3M. The stake represents ﹤0.01% of the portfolio and ranks #2954 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HALO as recently as Q3 2025.

Citadel Advisors first reported a position in HALO in Q2 2013 and has held it in 49 quarters since. The position peaked at $60.4M in Q4 2024. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Citadel Advisors held 191,051 shares of Halozyme worth $12.3M as of Q1 2026.
  • Halozyme was a new Citadel Advisors position in Q1 2026.
  • Halozyme made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2954 holding.
  • Citadel Advisors first reported a position in Halozyme in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Halozyme position peaked at $60.4M in Q4 2024.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.